---
title: "Shanghai Henlius Biotech’s HLX11 Receives FDA Approval for Breast Cancer Treatment"
type: "News"
locale: "zh-HK"
url: "https://longbridge.com/zh-HK/news/265879405.md"
description: "Shanghai Henlius Biotech's biosimilar product, HLX11, branded as POHERDY®, has received FDA approval for treating HER2-positive breast cancer. This milestone enhances the company's presence in the U.S. market and boosts collaboration with Organon LLC for commercial sales. The stock is rated Hold with a HK$66.00 price target. Shanghai Henlius focuses on biosimilars for cancer treatment and international expansion, with a market cap of HK$33.59B."
datetime: "2025-11-14T09:08:38.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/265879405.md)
  - [en](https://longbridge.com/en/news/265879405.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/265879405.md)
---

> 支持的語言: [简体中文](https://longbridge.com/zh-CN/news/265879405.md) | [English](https://longbridge.com/en/news/265879405.md)


# Shanghai Henlius Biotech’s HLX11 Receives FDA Approval for Breast Cancer Treatment

### Meet Your ETF AI Analyst

-   Discover how TipRanks' _ETF_ AI Analyst can help you make smarter investment decisions
-   Explore ETFs TipRanks' users love and see what insights the **_ETF_ AI Analyst** reveals about the ones you follow.

Shanghai Henlius Biotech, Inc. Class H ( (HK:2696) ) has shared an update.

Shanghai Henlius Biotech, Inc. has announced that its biosimilar product, HLX11 (pertuzumab-dpzb), branded as POHERDY® in the United States, has received FDA approval for use in treating HER2-positive early and metastatic breast cancer. This approval marks a significant milestone for the company, enhancing its international presence and influence, particularly in the U.S. market, and is expected to boost its collaboration with Organon LLC for commercial sales.

The most recent analyst rating on (HK:2696) stock is a Hold with a HK$66.00 price target. To see the full list of analyst forecasts on Shanghai Henlius Biotech, Inc. Class H stock, see the HK:2696 Stock Forecast page.

**More about Shanghai Henlius Biotech, Inc. Class H**

Shanghai Henlius Biotech, Inc. is a biotechnology company based in China, specializing in the development and commercialization of biosimilar products. The company focuses on producing biologics for the treatment of various cancers, with a strong emphasis on international market expansion.

**Average Trading Volume:** 1,567,991

**Technical Sentiment Signal:** Buy

**Current Market Cap:** HK$33.59B

### 相關股票

- [HENLIUS (02696.HK)](https://longbridge.com/zh-HK/quote/02696.HK.md)

## 相關資訊與研究

- [Henlius Wins Key EMA Backing for Cancer Drug Serplulimab in Europe](https://longbridge.com/zh-HK/news/280997570.md)
- [Shanghai Henlius Biotech Receives CSRC Approval for H Share Full Circulation](https://longbridge.com/zh-HK/news/272805634.md)
- [HKEX on Expanding ETF Offerings](https://longbridge.com/zh-HK/news/280764173.md)
- [Iantrek Advances New AlloSpanâ¢ Canal into U.S. Site Evaluations, Expanding Its Bio-Interventional Platform](https://longbridge.com/zh-HK/news/281185996.md)
- [Precise Biometrics Calls EGM to Approve Merger With Fingerprint Cards](https://longbridge.com/zh-HK/news/281003945.md)